
|Articles|December 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 12
- Volume 15
- Issue 12
Pharmion Purchases Cabrellis, US Developer of Amrubicin
Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Advertisement
BOULDER, ColoradoPharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Articles in this issue
over 19 years ago
Best Rx Most Cost-Effective: RTOGover 19 years ago
Grape Seed Found to Be a Natural Aromatase Inhibitorover 19 years ago
Drug Combination Prevents ER-Negative Tumors in Miceover 19 years ago
Democrats' Agenda May Stifle Efforts for More Ca Fundingover 19 years ago
No Loss of Efficacy With Synchronous Chemotherapy/ESPover 19 years ago
'Share Care' Difficult for Ca Survivors and Their Oncologistsover 19 years ago
Biomarkers Panel Promising for Detecting Pancreatic Caover 19 years ago
Preop Avastin/Tarceva in RCCover 19 years ago
Reovirus Agent Shows Activity in Phase I TrialAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
5






































































